STCube Inc (052020) - Cash Flow Conversion Efficiency
Based on the latest financial reports, STCube Inc (052020) has a cash flow conversion efficiency ratio of -0.064x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-5.06 Billion ≈ $-3.43 Million USD) by net assets (₩78.59 Billion ≈ $53.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
STCube Inc - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how STCube Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read STCube Inc debt and liabilities for a breakdown of total debt and financial obligations.
STCube Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of STCube Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oyak Yatirim Menkul Degerler AS
IS:OYYAT
|
-0.010x |
|
Oatly Group AB ADR
NASDAQ:OTLY
|
-0.324x |
|
SamsungFN REIT Co. Ltd.
KO:448730
|
N/A |
|
Panoro Energy ASA
F:1PZ
|
0.140x |
|
SSE PLC
LSE:SSE
|
0.091x |
|
HEBA Fastighets AB (publ)
ST:HEBA-B
|
0.002x |
|
Eventbrite Inc Class A
NYSE:EB
|
0.194x |
|
Home Invest Belgium - Sifi
BR:HOMI
|
0.024x |
Annual Cash Flow Conversion Efficiency for STCube Inc (2009–2024)
The table below shows the annual cash flow conversion efficiency of STCube Inc from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see 052020 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩94.28 Billion ≈ $63.89 Million |
₩-23.32 Billion ≈ $-15.80 Million |
-0.247x | +64.51% |
| 2023-12-31 | ₩35.31 Billion ≈ $23.93 Million |
₩-24.61 Billion ≈ $-16.68 Million |
-0.697x | -121.89% |
| 2022-12-31 | ₩51.22 Billion ≈ $34.71 Million |
₩-16.09 Billion ≈ $-10.90 Million |
-0.314x | +70.39% |
| 2021-12-31 | ₩16.16 Billion ≈ $10.95 Million |
₩-17.15 Billion ≈ $-11.62 Million |
-1.061x | -271.33% |
| 2020-12-31 | ₩36.03 Billion ≈ $24.41 Million |
₩-10.29 Billion ≈ $-6.97 Million |
-0.286x | -4165.71% |
| 2019-12-31 | ₩28.82 Billion ≈ $19.53 Million |
₩-192.99 Million ≈ $-130.79K |
-0.007x | +95.65% |
| 2018-12-31 | ₩38.70 Billion ≈ $26.23 Million |
₩-5.96 Billion ≈ $-4.04 Million |
-0.154x | +74.13% |
| 2017-12-31 | ₩19.12 Billion ≈ $12.96 Million |
₩-11.38 Billion ≈ $-7.71 Million |
-0.595x | -386.91% |
| 2016-12-31 | ₩29.24 Billion ≈ $19.81 Million |
₩6.07 Billion ≈ $4.11 Million |
0.207x | +203.54% |
| 2015-12-31 | ₩20.91 Billion ≈ $14.17 Million |
₩-4.19 Billion ≈ $-2.84 Million |
-0.200x | -182.38% |
| 2012-12-31 | ₩8.79 Billion ≈ $5.96 Million |
₩2.14 Billion ≈ $1.45 Million |
0.243x | +203.88% |
| 2011-12-31 | ₩9.97 Billion ≈ $6.76 Million |
₩-2.33 Billion ≈ $-1.58 Million |
-0.234x | -74.55% |
| 2010-12-31 | ₩11.74 Billion ≈ $7.95 Million |
₩-1.57 Billion ≈ $-1.07 Million |
-0.134x | -244.26% |
| 2009-12-31 | ₩16.63 Billion ≈ $11.27 Million |
₩1.55 Billion ≈ $1.05 Million |
0.093x | -- |
About STCube Inc
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a tech… Read more